US FDA Advisory Committees' Future: Drug-Agnostic Panels, More Debate Time

 
• By Sarah Karlin-Smith

FDA Commissioner Califf and some top deputies are angling for more advisory panels that would influence drug development programs rather than approval decisions. Califf also wants to adjust meeting formats so advisors have more time for in-depth discussions.

boats
The FDA is looking to “float all boats” with future non-drug specific advisory panel topics. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers